{"schema_version":"secwatch.filing_event.v1","accession":"0001576280-23-000186","form_type":"8-K","ticker":"GH","cik":"0001576280","company_name":"Guardant Health, Inc.","filed_at":"2023-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.601805+00:00","generated_at":"2026-06-08T20:41:13.638059+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Guardant Health Q3 revenue $143M (+22% YoY); raises FY 2023 guidance to $553-556M","bullets":["GAAP net loss $86.1M ($0.73/share) vs $162M ($1.58) YoY; non-GAAP loss $79.2M ($0.67).","Clinical test volume 43,900 (+35% YoY); biopharma tests 7,500 (+11%).","Precision oncology revenue up 31% YoY; Medicare appeal payment of $3.6M included.","FY 2023 revenue guidance raised to $553-556M (23-24% growth); cash $1.2B.","Launched Guardant360 in Japan/China; Japan approval as CDx for ENHERTU."],"urls":{"canonical":"https://secwatch.observer/filing/0001576280-23-000186","json":"https://secwatch.observer/filing/0001576280-23-000186.json","markdown":"https://secwatch.observer/filing/0001576280-23-000186.md","text":"https://secwatch.observer/filing/0001576280-23-000186.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576280/000157628023000186/0001576280-23-000186-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576280/000157628023000186/gh-20231106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T20:41:13.638059+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c0a3a702129d1d21fdfbbc049c2ad3db989cedc6","claim":"Guardant Health, Inc. reported the quarter ended September 30, 2023 results: revenue $143.0 million, net income $86.1 million, EPS $0.73 per share. Guidance raised.","evidence_excerpt":"tests, vast data sets and advanced analytics, today reported financial results for the quarter ended September 30, 2023. Third Quarter 2023 Financial Highlights • Revenue of $143.0 million for the third quarter of 2023, an increase of 22% over the third quarter of 2022 • Reported 43,900 tests to clinical customers and 7,500 tests to biopharmaceutical customers in","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1576280/000157628023000186/0001576280-23-000186-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Revenue","value":"$143.0 million"},{"label":"Net income","value":"$86.1 million"},{"label":"EPS","value":"$0.73 per share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}